血清CXCL10联合CXCL12检测对急性胰腺炎患者预后的预测价值

doi:10.3760/cma.j.cn441417-20240914-06031

摘要/Abstract

摘要：

目的　探讨血清CXC趋化因子配体（CXC chemokine ligand，CXCL）10联合CXCL12检测对急性胰腺炎（acute pancreatitis，AP）患者预后的预测价值。方法　选取2021年3月至2024年5月在渭南市第二医院收治的120例AP患者作为研究对象（AP组），其中男69例、女51例，年龄（54.47±7.12）岁；选择同期来院体检的120名健康者设为对照组，其中男66例、女54例，年龄（53.48±6.26）岁。将AP患者按病情严重程度分为轻症组78例和重症组42例，根据治疗1个月后的结果分为预后良好组99例和预后不良组21例。采用酶联免疫吸附测定法检测患者血清CXCL10和CXCL12水平，并通过多因素logistic回归分析评估影响AP患者预后的因素，受试者操作特征曲线（ROC）分析CXCL10和CXCL12联合检测对AP患者预后的预测效能。采用t检验、χ²检验或Fisher确切概率法进行统计比较。结果　AP组血清CXCL10、CXCL12水平高于对照组［（178.80±34.71）μg/L比（90.29±10.14）μg/L、（2.71±0.65）μg/L比（1.65±0.23）μg/L］，差异均有统计学意义（t=26.813、16.841，均P<0.05）。重症组血清CXCL10、CXCL12水平高于轻症组［（201.20±38.83）μg/L比（166.74±31.90）μg/L、（2.98±0.74）μg/L比（2.56±0.62）μg/L］，差异均有统计学意义（t=5.224、3.304，均P<0.05）。预后不良组血清CXCL10、CXCL12水平高于预后良好组［（216.42±41.10）μg/L比（170.82±33.55）μg/L、（3.13±0.78）μg/L比（2.62±0.60）μg/L］，差异均有统计学意义（t=5.432、3.348，均P<0.05）。多因素logistic回归分析表明，血清CXCL10、CXCL12均为影响AP患者预后的独立危险因素（均P<0.05）。ROC显示，CXCL10联合CXCL12预测灵敏度、特异度分别为90.5%、88.9%，AUC为0.944，均高于单独检测（均P<0.05）。结论　血清CXCL10联合CXCL12检测对急性胰腺炎患者预后的预测具有较高的临床应用价值。

关键词:

急性胰腺炎, CXC趋化因子配体10, CXC趋化因子配体12, 预测

Abstract:

Objective　To investigate the predictive value of serum CXC chemokine ligand 10 (CXCL10) and CXC chemokine ligand 12 (CXCL12) for prognosis of patients with acute pancreatitis (AP). Methods　A total of 120 patients with AP treated at Weinan Second Hospital from March 2021 to May 2024 were selected as an AP group, including 69 males and 51 females who were (54.47±7.12) years old. Additionally, 120 healthy individuals undergoing physical examinations at Weinan Second Hospital during the same period were selected as a control group, including 66 males and 54 females who were (53.48±6.26) years. The patients were categorized by severity into a mild group (78 cases) and a severe group (42 cases), and were divided into a good prognosis group (99 cases) and a poor prognosis group (21 cases) based on the 1-month treatment outcomes. The serum CXCL10 and CXCL12 levels were measured by the enzyme linked immunosorbent assay. The multivariate logistic regression analysis was performed to assess the factors influencing the patients' prognosis. The predictive performance of CXCL10 and CXCL12 for the patients' prognosis was analyzed using the receiver operating characteristic curves (ROC). Statistical analysis was conducted using t and χ² tests or Fisher's precision probability test. Results　The serum levels of CXCL10 and CXCL12 in the AP group were higher than those in the control group [(178.80±34.71) μg/L vs. (90.29±10.14) μg/L and (2.71±0.65) μg/L vs. (1.65±0.23) μg/L], with statistical differences (t=26.813 and 16.841; both P<0.05). The serum levels of CXCL10 and CXCL12 in the severe group were higher than those in the mild group [(201.20±38.83) μg/L vs. (166.74±31.90) μg/L and (2.98±0.74) μg/L vs. (2.56±0.62) μg/L], with statistical differences (t=5.224 and 3.304; both P<0.05). The serum levels of CXCL10 and CXCL12 in the poor prognosis group were higher than those in the good prognosis group [(216.42±41.10) μg/L vs. (170.82±33.55) μg/L and (3.13±0.78) μg/L vs. (2.62±0.60) μg/L], with statistical differences (t=5.432 and 3.348; both P<0.05). The multivariate logistic regression analysis showed that serum CXCL10 and CXCL12 were independent risk factors affecting the patients' prognosis (both P<0.05). The ROC results revealed that the sensitivity and specificity of CXCL10 combined with CXCL12 for predicting the poor prognosis in the patients were 90.5% and 88.9%, with an AUC of 0.944, which were higher than those of each one (all P<0.05). Conclusion　The combined detection of serum CXCL10 and CXCL12 has significant clinical value for predicting the prognosis of patients with AP.

Key words:

Acute pancreatitis, CXC chemokine ligand 10, CXC chemokine ligand 12, Prediction

祖渭东许博胡晓红.

血清CXCL10联合CXCL12检测对急性胰腺炎患者预后的预测价值 [J]. 国际医药卫生导报, 2025, 31(6): 1036-1040.

Zu Weidong, Xu Bo, Hu Xiaohong.

Predictive value of serum CXCL10 and CXCL12 for prognosis of patients with acute pancreatitis [J]. International Medicine and Health Guidance News, 2025, 31(6): 1036-1040.

参考文献

[1] 莫闲,杨闯. 急性胰腺炎发病机制及并发内脏静脉血栓研究进展[J]. 陕西医学杂志,2024,53(2):282-285. DOI:10.3969/j.issn.1000-7377.2024.02.030.
[2] 商和振,唐楠,陈增银,等. 重症急性胰腺炎评分量表及诊疗进展[J]. 腹部外科,2024,37(1):32-37. DOI:10.3969/j.issn.1003-5591.2024.01.007.
[3] Spampinato MD, Caputo F, Guarino M, et al. Predicting in-hospital mortality in patients with acute pancreatitis in the ED: a direct, retrospective comparison of four clinical and radiological prognostic scores[J]. Minerva Gastroenterol (Torino), 2024,70(2):147-157. DOI: 10.23736/S2724-5985.23.03389-2.
[4] Korbecki J, Kojder K, Kapczuk P, et al. The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-a review of literature[J]. Int J Mol Sci, 2021,22(2):843. DOI: 10.3390/ijms22020843.
[5] Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus[J]. Gut, 2013,62(1):102-111. DOI: 10.1136/gutjnl-2012-302779.
[6] Bai X, Jin M, Zhang H, et al. Evaluation of Chinese updated guideline for acute pancreatitis on management of moderately severe and severe acute pancreatitis[J]. Pancreatology, 2020,20(8):1582-1586. DOI: 10.1016/j.pan.2020.09.013.
[7] Hadke S, Sakharkar S, Raut A, et al. Case report on acute pancreatitis[J]. Journal of Pharmaceutical Research International, 2021, 33(60B): 3394-3398.
[8] 赵先林,朱世峰,康鸿鑫,等. 急性胰腺炎与表观遗传调控机制[J]. 临床肝胆病杂志,2020,36(1):227-230. DOI:10.3969/j.issn.1001-5256.2020.01.054.
[9] Iannuzzi JP, King JA, Leong JH, et al. Global incidence of acute pancreatitis is increasing over time: a systematic review and meta-analysis[J]. Gastroenterology, 2022,162(1):122-134. DOI: 10.1053/j.gastro.2021.09.043.
[10] Sonwani NS, Thakur KS, Ateriya N, et al. Acute haemorrhagic pancreatitis presenting as sudden death[J]. Journal of Indian Academy of Forensic Medicine, 2023, 45(2): 190-192.
[11] Gliem N, Ammer-Herrmenau C, Ellenrieder V, et al. Management of severe acute pancreatitis: an update[J]. Digestion, 2021,102(4):503-507. DOI: 10.1159/000506830.
[12] Szatmary P, Grammatikopoulos T, Cai W,et al. Acute pancreatitis: diagnosis and treatment[J]. Drugs, 2022,82(12):1251-1276. DOI: 10.1007/s40265-022-01766-4.
[13] 谷阁,王润之,张梦辉,等. 血清淀粉样蛋白A联合APACHEⅡ评分对急性胰腺炎预后的预测价值[J]. 中国急救复苏与灾害医学杂志,2022,17(12):1626-1629. DOI:10.3969/j.issn.1673-6966.2022.12.023.
[14] 陈宇,李响,宁佳曦,等. BISAP评分、NIR、HCT及钙离子评估急性胰腺炎严重程度及预后的临床价值[J]. 川北医学院学报,2024,39(1):117-119,123. DOI:10.3969/j.issn.1005-3697.2024.01.028.
[15] Han B, Yang W, Wang H, et al. Construction and evaluation of a prognostic model for severe acute pancreatitis based on CT scores and inflammatory factors[J]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 2023,35(1):82-87. DOI: 10.3760/cma.j.cn121430-20220411-00351.
[16] Kochumon S, Madhoun AA, Al-Rashed F, et al. Adipose tissue gene expression of CXCL10 and CXCL11 modulates inflammatory markers in obesity: implications for metabolic inflammation and insulin resistance[J]. Ther Adv Endocrinol Metab, 2020,11:2042018820930902. DOI: 10.1177/2042018820930902.
[17] Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention[J]. Cell Mol Immunol, 2023,20(3):217-251. DOI: 10.1038/s41423-023-00974-6.
[18] Huang H, Zhou W, Chen R, et al. CXCL10 is a tumor microenvironment and immune infiltration related prognostic biomarker in pancreatic adenocarcinoma[J]. Front Mol Biosci, 2021,8:611508. DOI: 10.3389/fmolb.2021.611508.
[19] D'Alterio C, Giardino A, Scognamiglio G,et al. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in pancreatic cancer: CXCL12 predicts survival of radically resected patients[J]. Cells, 2022,11(21):3340. DOI: 10.3390/cells11213340.
[20] 朱芳丽,马厉英,马晓莹,等. 急性胰腺炎患者血清CXC趋化因子配体10和CC类趋化因子22水平与疾病严重程度关系及临床诊断价值研究[J]. 陕西医学杂志,2024,53(6):788-792. DOI:10.3969/j.issn.1000-7377.2024.06.014.